Alnylam Pharmaceuticals (ALNY) Net Cash Flow Growth (1y) (2010 - 2026)
Alnylam Pharmaceuticals (ALNY) Net Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 53.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.46% |
| Dec 31, 2025 | 247.29% |
| Sep 30, 2025 | 225.15% |
| Jun 30, 2025 | -77.17% |
| Mar 31, 2025 | 132.89% |
| Dec 31, 2024 | 49.58% |
| Sep 30, 2024 | -69.56% |
| Jun 30, 2024 | 2,124.43% |
| Mar 31, 2024 | 38.76% |
| Dec 31, 2023 | -10.92% |
| Sep 30, 2023 | -22.97% |
| Jun 30, 2023 | -128.43% |
| Mar 31, 2023 | 30.79% |
| Dec 31, 2022 | 23.15% |
| Sep 30, 2022 | 40.99% |
| Jun 30, 2022 | -86.22% |
| Mar 31, 2022 | -150.73% |
| Dec 31, 2021 | -8,701.27% |
| Sep 30, 2021 | 507.49% |
| Jun 30, 2021 | 224.56% |